Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259
Recruiting
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hypertrophic Cardiomyopathy
Register for Updates
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
NCT05727761
Recruiting
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in \> 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Oral Leukoplakia
Register for Updates
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338
Recruiting
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effect... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
07/10/2025
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota
Conditions: Childhood Medulloblastoma
Register for Updates
Intracardiac Flow Assessment in Cardiac Amyloidosis
NCT05379101
Recruiting
The primary objective of this study is to define the intracardiac flow imaging biomarkers in cardiac amyloidosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Amyloidosis Cardiac, Healthy Adults
Register for Updates
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
Recruiting
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Castration Resistant Metastatic Prostate Cancer
Register for Updates
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
NCT03858205
Recruiting
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Minnesota - Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
Register for Updates
A Study of Pyridostigmine in Postural Tachycardia Syndrome
NCT00409435
Recruiting
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Gender:
ALL
Ages:
Between 15 years and 55 years
Trial Updated:
07/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Postural Tachycardia Syndrome
Register for Updates
Deciphering Preserved Autonomic Function After Multiple Sclerosis
NCT07012135
Recruiting
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the bo... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/09/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Register for Updates
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
NCT06997068
Recruiting
This phase II trial gathers information on the feasibility, safety, and effect of giving methotrexate, erlotinib, and celecoxib in treating oral cavity cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic) among rural Midwest patients. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8
Register for Updates
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875
Recruiting
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Burnsville, Minnesota
Conditions: HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06593600
Recruiting
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/09/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Postural Orthostatic Tachycardia Syndrome (POTS)
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Duluth, Minnesota
Conditions: Non-small Cell Lung Cancer
Register for Updates